search
Back to results

Confocal Laser Endomicroscopy for Brain Tumors (CONVIVO)

Primary Purpose

Brain Tumor, Surgery, Convivo System

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
CONVIVO
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Brain Tumor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patient is undergoing neurosurgery for a suspected brain tumor and amenable to surgical resection by fluorescent guided technique
  • The patient has an indication for tumor resection
  • Macroscopic tumor visualization using sodium fluorescein is planned, concentration 5-10mg/kg
  • The patient is older than 18 years
  • Written consent

Exclusion Criteria:

  • Stereotactic biopsy procedure
  • Patients with any kind of contraindication to the use of fluorescein sodium
  • Vulnerable persons (pregnant women, patients with Glasgow Coma Scale below 14)
  • Participation in other ongoing clinical trials with one exception: double inclusions are allowed provided that no interaction with NaF is to be expected
  • People who do not want to participate in the study
  • Tumors that do not exactly match the inclusion criteria
  • Emergency procedures in which no consent was obtained before the operation.
  • Multiple surgeries on the same patient.

Sites / Locations

  • Dep. of Neurosurgery, Bern University Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CONVIVO

Arm Description

tumor tissue identification with the CONVIVO system

Outcomes

Primary Outcome Measures

Identification of tumor tissue
Identification of tumor tissue versus non-affected tissue by the CONVIVO system in comparison to the histopathology of frozen section

Secondary Outcome Measures

Accuracy of CONVIVO results
Accuracy of CONVIVO results compared with results of final tumor histopathology
Time for tissue visualization with the CONVIVO system
Intraoperative time for the tissue visualization with the CONVIVO system
Rate of unclear visualizations
Rate of unclear visualizations in %

Full Information

First Posted
February 20, 2020
Last Updated
July 3, 2023
Sponsor
Insel Gruppe AG, University Hospital Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT04280952
Brief Title
Confocal Laser Endomicroscopy for Brain Tumors
Acronym
CONVIVO
Official Title
Confocal Laser Endomicroscopy for Brain Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
June 5, 2020 (Actual)
Primary Completion Date
June 13, 2023 (Actual)
Study Completion Date
June 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The prognosis of glioblastoma patients highly depends on resection extent. Various strategies have been introduced to overcome the dilemma of intraoperative tumor identification. In gastroenterology, confocal laser endomicroscopy (CLE) allows precise differentiation of tumor tissue from surrounding mucosa in various diseases. Combining high-definition white light endoscopy with CLE significantly increases sensitivity and specificity compared with the sole application of high-definition white light endoscopy. CLE was recently introduced to neurosurgical applications. Although still in an early stage of clinical application, this technique has proven to be capable of differentiating various tumor entities in animal models as well as human tissue samples. CLE allows visualization of the underlying tissue on a microscopic scale, receiving information on the microstructure as well as cellular components. However, the clinical importance of this technique for its application in neurosurgery will be demonstrated in this clinical trial.
Detailed Description
Background: The prognosis of glioblastoma patients highly depends on resection extent. Various strategies have been introduced to overcome the dilemma of intraoperative tumor identification. In gastroenterology, confocal laser endomicroscopy (CLE) allows precise differentiation of tumor tissue from surrounding mucosa in various diseases. Combining high-definition white light endoscopy with CLE significantly increases sensitivity and specificity compared with the sole application of high-definition white light endoscopy. CLE was recently introduced to neurosurgical applications. Although still in an early stage of clinical application, this technique has proven to be capable of differentiating various tumor entities in animal models as well as human tissue samples. CLE allows visualization of the underlying tissue on a microscopic scale, receiving information on the microstructure as well as cellular components. However, the clinical importance of this technique for its application in neurosurgery still needs to be demonstrated Methods: Intravenous injection dose of fluorescein sodium. For every operation the investigators plan to take pictures with the CONVIVO system before taking the material for standard frozen section and definitive histopathology. These pictures will be evaluated by a pathologist afterwards. Objectives: The primary objective of this trial is to demonstrate, that the CONVIVO system allows identification of tumor tissue. The secondary objectives are procedural aspects and handling issues covering the usability.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Tumor, Surgery, Convivo System, Laser Endomicroscopy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Tumor tissue identification with CONVIVO system
Masking
None (Open Label)
Allocation
N/A
Enrollment
174 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CONVIVO
Arm Type
Experimental
Arm Description
tumor tissue identification with the CONVIVO system
Intervention Type
Device
Intervention Name(s)
CONVIVO
Intervention Description
tumor tissue with the CONVIVO system
Primary Outcome Measure Information:
Title
Identification of tumor tissue
Description
Identification of tumor tissue versus non-affected tissue by the CONVIVO system in comparison to the histopathology of frozen section
Time Frame
End of surgery
Secondary Outcome Measure Information:
Title
Accuracy of CONVIVO results
Description
Accuracy of CONVIVO results compared with results of final tumor histopathology
Time Frame
14 days after surgery
Title
Time for tissue visualization with the CONVIVO system
Description
Intraoperative time for the tissue visualization with the CONVIVO system
Time Frame
End of surgery
Title
Rate of unclear visualizations
Description
Rate of unclear visualizations in %
Time Frame
14 days after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient is undergoing neurosurgery for a suspected brain tumor and amenable to surgical resection by fluorescent guided technique The patient has an indication for tumor resection Macroscopic tumor visualization using sodium fluorescein is planned, concentration 5-10mg/kg The patient is older than 18 years Written consent Exclusion Criteria: Stereotactic biopsy procedure Patients with any kind of contraindication to the use of fluorescein sodium Vulnerable persons (pregnant women, patients with Glasgow Coma Scale below 14) Participation in other ongoing clinical trials with one exception: double inclusions are allowed provided that no interaction with NaF is to be expected People who do not want to participate in the study Tumors that do not exactly match the inclusion criteria Emergency procedures in which no consent was obtained before the operation. Multiple surgeries on the same patient.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kathleen Seidel, MD
Organizational Affiliation
Principal Investigator
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dep. of Neurosurgery, Bern University Hospital
City
Bern
ZIP/Postal Code
3010
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Confocal Laser Endomicroscopy for Brain Tumors

We'll reach out to this number within 24 hrs